Tuesday, June 18, 2024

Institute for Clinical and Economic Review’s May 2024 Updates on Key Assessments of Medical Treatments

Similar articles

In May 2024, the Institute for Clinical and Economic Review (ICER) released several important updates regarding their assessments of various treatments. These assessments are pivotal in providing comprehensive information on the comparative clinical effectiveness and value of new medical treatments. By thoroughly evaluating these treatments, ICER aims to offer critical evidence-based insights and recommendations that can significantly influence decision-making processes within the healthcare sector.

The organization’s work ensures that stakeholders, including healthcare providers, policymakers, and patients, are well-informed about the potential benefits, risks, and cost-effectiveness of new treatments. This, in turn, helps to optimize healthcare delivery by promoting the use of interventions that provide the greatest overall benefit. ICER’s rigorous and transparent assessment process is essential in fostering an informed healthcare system that prioritizes patient outcomes and resource efficiency.

ICER announced that it will evaluate the clinical effectiveness and value of tabelecleucel (tab-cel®) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The assessment will be discussed during the New England CEPAC meeting in November 2024. The Draft Scoping Document, outlining the assessment plan, is open for public comment. This initiative aims to ensure comprehensive stakeholder engagement and refine the assessment scope to reflect diverse perspectives. Building on its commitment to thorough and inclusive evaluations, ICER also released a Draft Evidence Report evaluating the efficacy and value of imetelstat (Geron Corporation) for treating anemia in myelodysplastic syndrome.

ICER released a Draft Evidence Report evaluating the efficacy and value of imetelstat (Geron Corporation) for treating anemia in myelodysplastic syndrome. The report, part of an eight-month assessment process, is open for public comment until June 10, 2024. The findings within this draft are preliminary, and a public webinar on May 22, 2024, will discuss the initial results. The final Evidence Report will incorporate public feedback and be published in July 2024.

Institute for Clinical and Economic Review

ICER published a revised Evidence Report on the effectiveness of 3,4-Methylenedioxymethamphetamine-assisted psychotherapy (MDMA-AP) for post-traumatic stress disorder (PTSD). The report highlighted substantial uncertainties regarding clinical trial results, preventing ICER from recommending a health-benefit price benchmark. The assessment will be reviewed at a public meeting on May 30, 2024. ICER concluded that the current publicly available evidence is insufficient to determine the overall net benefit of MDMA-AP. Continuing its rigorous evaluation efforts, ICER published a revised Evidence Report on the effectiveness of MDMA-AP for post-traumatic stress disorder.

ICER released a revised Evidence Report on ensifentrine (Verona Pharma) for treating chronic obstructive pulmonary disease (COPD). The report indicates that ensifentrine reduces exacerbations and is well-tolerated but notes uncertainties about its additional benefits when combined with unstudied inhaler therapies. Ensifentrine has not yet been FDA-approved, and ICER calculated a health-benefit price benchmark of $7,500 to $12,700 per year. This report will be reviewed at a public meeting.

The news from ICER in May 2024 underscores the organization’s commitment to evaluating the clinical effectiveness and economic value of new medical treatments. By engaging with stakeholders and incorporating public feedback, ICER ensures that its assessments are comprehensive and reflective of diverse perspectives. These evaluations are crucial in guiding healthcare providers, policymakers, and patients in making informed decisions about the use of new treatments. The ongoing assessments of tabelecleucel, imetelstat, MDMA-AP, and ensifentrine highlight the continuous effort to advance medical care and improve patient outcomes across various conditions.

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article